A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

NCT ID: NCT01526057

Last Updated: 2019-11-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

220 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-03-20

Study Completion Date

2014-05-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study, patients with moderate to severe rheumatoid arthritis who are being treated with methotrexate will receive 2 intravenous treatments with either PF-05280586 or Rituxan (Rituximab) or MabThera (Rituximab). During the course of the study, the effects of the drugs will be assessed by sampling the levels of drug in the blood, blood cell counts, and by comparing these levels among the different treatments. Safety, tolerability and immunologic response also will be evaluated throughout.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A - PF-05280586

Group Type EXPERIMENTAL

PF-05280586

Intervention Type BIOLOGICAL

1000 mg, IV on days 1 and 15

B - Rituximab EU

Group Type ACTIVE_COMPARATOR

MabThera

Intervention Type BIOLOGICAL

1000 mg, IV on days 1 and 15

C- Rituximab-US

Group Type ACTIVE_COMPARATOR

Rituxan

Intervention Type BIOLOGICAL

1000 mg, IV on days 1 and 15

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PF-05280586

1000 mg, IV on days 1 and 15

Intervention Type BIOLOGICAL

MabThera

1000 mg, IV on days 1 and 15

Intervention Type BIOLOGICAL

Rituxan

1000 mg, IV on days 1 and 15

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of rheumatoid arthritis
* Meets Class I, II or III of the ACR 1991 Revised Criteria
* RA seropositivity
* Stable dose of methotrexate
* Inadequate response to TNF inhibitors

Exclusion Criteria

* Any prior treatment with lymphocyte depleting therapies
* History of active TB infection
* Known or screen test positive for specific viruses or indicators of viral infection
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Bermingham

Birmingham, Alabama, United States

Site Status

University of Alabama at Birmingham - Arthritis Clinical Intervention Program (ACIP) SRC 076

Birmingham, Alabama, United States

Site Status

Rheumatology Associates of North Alabama, PC

Huntsville, Alabama, United States

Site Status

ArthroCare, Arthritis Care & Research, PC

Gilbert, Arizona, United States

Site Status

Mercy Clinic Hot Springs Communities

Hot Springs, Arkansas, United States

Site Status

UCLA David Geffen School of Medicine

Los Angeles, California, United States

Site Status

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

Site Status

Desert Medical Advances

Palm Desert, California, United States

Site Status

Advances In Medicine

Rancho Mirage, California, United States

Site Status

New England Research Assoc. LLC

Trumbull, Connecticut, United States

Site Status

Arthritis Associates

Orlando, Florida, United States

Site Status

University of South Florida - College of Medicine, Frank and Carol Morsani Center

Tampa, Florida, United States

Site Status

Loyola Center for Health at Burr Ridge

Burr Ridge, Illinois, United States

Site Status

Loyola Medical Medical Center Outpatient Center

Maywood, Illinois, United States

Site Status

Loyola University Medical Center Pharmacy

Maywood, Illinois, United States

Site Status

Illinois Bone and Joint Institute

Morton Grove, Illinois, United States

Site Status

Loyola Center for health at Oakbrook Terrace North

Oakbrook Terrace, Illinois, United States

Site Status

Bluegrass Community Research, Inc.

Lexington, Kentucky, United States

Site Status

Klein & Associates, M.D., P.A.

Cumberland, Maryland, United States

Site Status

Klein & Associates, M.D., P.A.

Hagerstown, Maryland, United States

Site Status

Clinical Pharmacology Study Group

Worcester, Massachusetts, United States

Site Status

UMass Memorial Medical Center - Memorial Campus

Worcester, Massachusetts, United States

Site Status

UMass Memorial Medical Center-Rheumatology Center-Memorial Campus

Worcester, Massachusetts, United States

Site Status

Bronson Internal Medicine & Rheumatology

Battle Creek, Michigan, United States

Site Status

Rheumatology/Arthritis Center

Lansing, Michigan, United States

Site Status

University Of Nevada School Of Medicine

Las Vegas, Nevada, United States

Site Status

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, United States

Site Status

North Shore-LIJ Health System - Division of Rheumatology and Allergy-Clinical Immunology

Great Neck, New York, United States

Site Status

Box Arthritis & Rheumatology of the Carolinas, PLLC

Charlotte, North Carolina, United States

Site Status

Hickory Family Practice Associates

Hickory, North Carolina, United States

Site Status

PMG Research of Hickory, LLC - PI's Main Office (Subject visit, IP Storage, Infusion, & Lab Draws)

Hickory, North Carolina, United States

Site Status

PMG Research of Hickory

Hickory, North Carolina, United States

Site Status

Cincinnati Rheumatic Disease Study Group, Inc.

Cincinnati, Ohio, United States

Site Status

Health Research of Oklahoma

Oklahoma City, Oklahoma, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

The Arthritis Group

Philadelphia, Pennsylvania, United States

Site Status

Clinical Research Center of Reading, LLP

Wyomissing, Pennsylvania, United States

Site Status

Arthritis Associates, PLLC

Hixson, Tennessee, United States

Site Status

Arthritis Clinic

Jackson, Tennessee, United States

Site Status

West Tennessee Research Institute

Jackson, Tennessee, United States

Site Status

Metroplex Clinical Research Center

Dallas, Texas, United States

Site Status

Center For Clinical Trials Of Houston

Houston, Texas, United States

Site Status

Southwest Rheumatology Research LLC.

Mesquite, Texas, United States

Site Status

Rheumatology Research Unit

Maroochydore, Queensland, Australia

Site Status

The Queen Elizabeth Hospital, Department of Rheumatology

Woodville South, South Australia, Australia

Site Status

St. Vincent's Hospital (Melbourne)

Fitzroy, Victoria, Australia

Site Status

Pharmacie Matte et Petit

Québec, Quebec, Canada

Site Status

Centre de Rhumatologie St-Louis

Québec, Quebec, Canada

Site Status

Centre de Rhumatologie de l'Est du Quebec

Rimouski, Quebec, Canada

Site Status

Clinique Medicale du Phare

Rimouski, Quebec, Canada

Site Status

Centre de Recherche Musculo-Squelettique

Trois-Rivières, Quebec, Canada

Site Status

Clinica Medellin S.A Sede Centro

Medellín, Antioquia, Colombia

Site Status

Mix Supplier S.A

Medellín, Antioquia, Colombia

Site Status

Rodrigo Botero S.A.S.

Medellín, Antioquia, Colombia

Site Status

Cediul S.A.

Barranquilla, Atlántico, Colombia

Site Status

Centro de Reumatologia y Ortopedia

Barranquilla, Atlántico, Colombia

Site Status

Clinica Bonnadona - Prevenir S.A.

Barranquilla, Atlántico, Colombia

Site Status

Clinica de la Costa Ltdz.

Barranquilla, Atlántico, Colombia

Site Status

IPS Centro Integral de Reumatologia del Cairbe, CIRCARIBE S.A.S.

Barranquilla, Atlántico, Colombia

Site Status

Sabbag Radiologos Ltda.

Barranquilla, Atlántico, Colombia

Site Status

Cerid S.A.

Barranquilla, Colombia, Atlántico, Colombia

Site Status

Congregacion de las Hemanas Franciscanas Misioneras de Maria Auxiliadora - Clinica La Asuncion

Barranquilla, Colombia, Atlántico, Colombia

Site Status

IPS Clinica General del Norte S.A.

Barranquilla, Colombia, Atlántico, Colombia

Site Status

Schlosspark-Klinik GMBH, Internal Medicine II

Berlin, , Germany

Site Status

The Chaim Sheba Medical Center Department of Internal Medicine B

Ramat Gan, , Israel

Site Status

Cliditer, S.A. de C.V.

México, D.F., Mexico

Site Status

Private Office

Guadalajara, Jalisco, Mexico

Site Status

Centro De Investigacion Y Atencion Integral Durango CIAID

Durango, , Mexico

Site Status

Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.

San Luis Potosí City, , Mexico

Site Status

LLC CDCR "Healthy Joints"

Novosibirsk, Novosibirsk Oblast, Russia

Site Status

GBUZ City Clinical Hospital #7

Kazan', Tatarstan Republic, Russia

Site Status

State Institution of Healthcare "Regional Clinical Hospital for Wars' Veterans"

Kemerovo, , Russia

Site Status

State Budgetary Institution of Healthcare of Nizhegorodskiy Region

Nizhny Novgorod, , Russia

Site Status

St. Petersburg state Healthcare lnstitution 'Clinical Rheumatology Hospital No25

Saint Petersburg, , Russia

Site Status

Llc Ava-Peter

Saint Petersburg, , Russia

Site Status

State Institute of Healthcare Samara Regional Clinical Hospital named after M.I.Kalinin

Samara, , Russia

Site Status

Regional State Budget Institution of Healthcare "Tomsk Regional Clinical Hospital"

Tomsk, , Russia

Site Status

Panorama Medical Centre

Panorama, CAPE TOWN, South Africa

Site Status

Dr. Jan Fourie Medical Centre

Dundee, KwaZulu-Natal, South Africa

Site Status

Bexley Wing - St. James's University Hospital

Leeds, UK, United Kingdom

Site Status

Pharmacy Department, Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust

Leeds, , United Kingdom

Site Status

"The University of Leeds,

Leeds, , United Kingdom

Site Status

Pharmacy Dispensing - Bexley Wing - St. James's University Hospital

Leeds, , United Kingdom

Site Status

Whipps Cross University Hospital

London, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Australia Canada Colombia Germany Israel Mexico Russia South Africa United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Williams JH, Hutmacher MM, Zierhut ML, Becker JC, Gumbiner B, Spencer-Green G, Melia LA, Liao KH, Suster M, Yin D, Li R, Meng X. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab. Br J Clin Pharmacol. 2016 Dec;82(6):1568-1579. doi: 10.1111/bcp.13094. Epub 2016 Sep 22.

Reference Type DERIVED
PMID: 27530379 (View on PubMed)

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ICON 9002/010

Identifier Type: -

Identifier Source: secondary_id

2011-002896-40

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

B3281001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.